SCHEMBL4666187

SCHEMBL4666187

Nc1ccc(Nc2ccncn2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAD52 P43351 1/20 0.59
▸ MKNK1 Q9BUB5 9/20 0.48
▸ MKNK2 Q9HBH9 2/20 0.47
▸ HSP90AA1 P07900 1/20 0.43
▸ MAPT P10636 3/20 0.42
▸ POLB P06746 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ HTT P42858 2/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ ALOX12 P18054 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ ROCK1 Q13464 2/20 0.41
▸ BCL6 P41182 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14843891 0.84 MKNK1 (0.49) RAD52MKNK1MKNK2KDRMPL
SCHEMBL30611577 0.81 MEN1 (0.56) MKNK1MKNK2MAPTALDH1A1HTT
SCHEMBL27606911 0.80 MKNK1 (0.47) MKNK1MKNK2POLBALDH1A1L3MBTL1
SCHEMBL1323687 0.80 MAPT (0.53) MKNK1MAPTALDH1A1CYP1A2CYP3A4
SCHEMBL4630887 0.79 GSK3A (0.53) MKNK1MKNK2HSP90AA1HTTCYP1A2
SCHEMBL13434906 0.78 ROCK1 (0.61) MKNK1ROCK1MPL
SCHEMBL147860 0.77 MKNK1 (0.44) MKNK1MKNK2KDRMPL
Hydrochloric Acid SCHEMBL7857018 0.77 GSK3A (0.51) MKNK1MKNK2HSP90AA1HTTCYP1A2
SCHEMBL23867504 0.77 RAB9A (0.46) MKNK1MKNK2HTTCYP1A2CYP3A4
SCHEMBL21925684 0.77 MKNK1 (0.48) MKNK1MKNK2KDRMPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633201-B2 Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-01-21 — — US disclosed
US-20100056548-A1 THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2010-03-04 — — US disclosed
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 — — US disclosed
EP-1709007-A1 N-4-(6-(HETEO)ARYL-PYRIMIDIN-4-YLAMINOPHENYL)-BENZENESULFONAMIDES AS KINASE INHIBITORS Altana Pharma AG (DE) 2006-10-11 — — EP disclosed
WO-2005070900-A1 N-4-(6- (HETEO) ARYL-PYRIMIDIN-4-YLAMINOPHENYL) -BEZENESULFONAMIDES AS KINASE INHIBITORS ALTANA PHARMA AG (DE) 2005-08-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 RAD52 3125/4885MKNK1 287/4885MKNK2 265/4885
US-20100056548-A1 THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS CMPK1, DTYMK, NEK9 RAD52 2724/4885MKNK1 29/4885MKNK2 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback